Soligenix, Inc., said on Wednesday that its Chief Executive Officer Christopher Schaber will present at the 16th Annual BIO CEO Investor Conference on Monday in New York City.
The BIO CEO Investor Conference is organized by the Biotechnology Industry Association. The conference provides an opportunity for biotechnology companies to network with banks and investors to raise capital. According to BIO's website, 1,400 people attended the 2013 conference, with 700 investors.
Soligenix is a biopharmaceutical company that develops products to treat inflammatory diseases, biodefense vaccines and therapeutics.
The company is currently focusing on developing prevention and treatment medications for pediatric Crohn's disease, acute radiation enteritis, chronic Graft-versus-Host disease and oral mucositis.
Soligenix is also working toward vaccines for biotoxins such as ricin and anthrax. The research for the two treatments is the subject of a $9.4 million grant from the National Institute of Allergy and Infectious Disease. The company's research and development is in accordance with the Biomedical Advanced Research and Development Authority Strategic Plan of 2011-2016.
Schaber's presentation will be webcast live and available for replay for one hour following the presentation.